Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Compass Therapeutics (NASDAQ:CMPX) announced its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06, Zacks reports.

Compass Therapeutics Price Performance

Shares of CMPX stock traded up $0.03 during trading on Wednesday, reaching $3.82. The company had a trading volume of 2,893,363 shares, compared to its average volume of 1,451,090. The firm’s 50 day simple moving average is $3.74 and its two-hundred day simple moving average is $2.94. Compass Therapeutics has a one year low of $1.27 and a one year high of $4.86. The company has a market capitalization of $528.24 million, a PE ratio of -8.49 and a beta of 1.48.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CMPX shares. D. Boral Capital reissued a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a report on Wednesday. Compass Point set a $10.00 price objective on Compass Therapeutics in a research report on Monday, October 6th. Guggenheim raised their price target on Compass Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, August 12th. Lifesci Capital initiated coverage on Compass Therapeutics in a research note on Monday, October 6th. They set an “outperform” rating and a $10.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.90.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Creative Planning bought a new position in Compass Therapeutics in the 2nd quarter worth approximately $30,000. Strs Ohio acquired a new stake in shares of Compass Therapeutics during the 1st quarter worth approximately $34,000. Marex Group plc acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth approximately $61,000. XTX Topco Ltd acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth approximately $84,000. Finally, Invesco Ltd. grew its holdings in shares of Compass Therapeutics by 58.1% during the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock worth $153,000 after purchasing an additional 21,578 shares in the last quarter. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.